LGALS3BP and lung carcinoma: Finally, LGALS3BP appeared to be involved in resistance to 17-AAG (17-N-Allylamino-17- demethoxygeldanamycin), an HSP90 inhibitor tested in phase II/III clinical trials in lung cancer [29].